GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Product-specific reference

Rimegepant orally disintegrating tablets (Nurtec ODT)

Read renal action and limits
Local official-label summarySource retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons

Nurtec ODT / Nurtec

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

NURTEC-ODT: source applicability and renal evidence limits

CrCl <15: avoid; ESRD and dialysis not studied. The RX mirror is not independent corroboration of the matched label.

Before applying: Check indication-specific frequency and interacting drugs.

Evidence for this qualification

Selected-source comparison; independent clinician adjudication pending.

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

NURTEC-ODT: selected primary-label renal guidance and limits

This source only - not a merged recommendation

What matters first

Product: Adult NURTEC ODT for its labeled migraine uses; an orally disintegrating tablet, not an intranasal CGRP product.

Renal action / finding
No renal adjustment above the ESRD restriction.
Evidence or dialysis limit
CrCl <15: avoid; ESRD and dialysis not studied.
Monitoring / application
Check indication-specific frequency and interacting drugs.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Product / population
Adult NURTEC ODT for its labeled migraine uses; an orally disintegrating tablet, not an intranasal CGRP product.
Renal measure
CrCl, mL/min; ESRD avoidance below 15
Source revision
Revision date not captured in selected review; retrieval date is not revision date.
Retrieved
2026-11-07 (not the revision date)
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Before using this finding

CrCl <15: avoid; ESRD and dialysis not studied.

Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.

Section 8.7

No renal adjustment is required in mild, moderate or severe impairment. ESRD and dialysis populations have not been studied; avoid use with CrCl <15 mL/min. Do not infer a post-dialysis supplemental dose from low dialyzability. Preserve indication-specific frequency limits and interaction restrictions.

Source revision: Revision date not captured in selected review; retrieval date is not revision date. | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ef08e09-1098-35cc-e053-2a95a90a3e1d

Scope: Selected sections checked against the identified source; not a complete monograph or independent clinician approval. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

NURTEC-ODT: selected primary-label renal guidance and limits

Source retrieved 2026-11-07 - confirm current applicability

No dialysis regimen established in selected content

Read the source and its limits

NURTEC-ODT: selected RX renal passage

Source retrieved 2026-11-07 - confirm current applicability

No dialysis regimen established in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

NURTEC-ODT: selected primary-label renal guidance and limits

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Before using this finding

CrCl <15: avoid; ESRD and dialysis not studied.

Dialysis evidence: No dialysis regimen established in selected content

Adult NURTEC ODT for its labeled migraine uses; an orally disintegrating tablet, not an intranasal CGRP product.

Renal method: CrCl, mL/min; ESRD avoidance below 15
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
GlobalRPh RX List

NURTEC-ODT: selected RX renal passage

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Before using this finding

CrCl <15: avoid; ESRD and dialysis not studied.

Dialysis evidence: No dialysis regimen established in selected content

Adult NURTEC ODT for its labeled migraine uses; an orally disintegrating tablet, not an intranasal CGRP product.

Renal method: CrCl, mL/min; ESRD avoidance below 15
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

NURTEC-ODT: source applicability and renal evidence limits

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Official source

NURTEC-ODT: selected primary-label renal guidance and limits

Adult NURTEC ODT for its labeled migraine uses; an orally disintegrating tablet, not an intranasal CGRP product.

Method: CrCl, mL/min; ESRD avoidance below 15

Read this complete source summary
Rxlist source

NURTEC-ODT: selected RX renal passage

Adult NURTEC ODT for its labeled migraine uses; an orally disintegrating tablet, not an intranasal CGRP product.

Method: CrCl, mL/min; ESRD avoidance below 15

Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeRimegepant orally disintegrating tablets (Nurtec ODT) - selected U.S. label sectionsNURTEC-ODT: selected primary-label renal guidance and limitsNURTEC-ODT: selected RX renal passage
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ef08e09-1098-35cc-e053-2a95a90a3e1d

Product and population scope

Adult NURTEC ODT; acute and preventive dosing frequencies are not interchanged.

RDM32-rimegepant-nurtec-odt-scope · Source section: Editorial scope for the selected U.S. labelRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Rimegepant orally disintegrating tablets (Nurtec ODT) - selected U.S. label sections

Open original reference

Open / share this exact local source

U.S. product labeling / DailyMed · Adult NURTEC ODT; acute and preventive dosing frequencies are not interchanged.

Renal method: Creatinine clearance in mL/min for ESRD restriction
Source date: Revision not captured; retrieval date is not the revision date.
Retrieved: 2026-09-05

Local label summary; independent clinical review pending. Not a two-source validated protocol.

Renal restriction and evidence gap

No renal adjustment is required for mild, moderate or severe impairment. Avoid use in ESRD with CrCl below 15 mL/min. ESRD and dialysis patients have not been studied.

RDM32-rimegepant-nurtec-odt-1 · Source locator: 8.7

Indication and interaction limit

A renal no-adjustment statement does not change the indication-specific dosing frequency or interacting-drug restrictions.

RDM32-rimegepant-nurtec-odt-2 · Source locator: 2; 7; 8.7

Source-specific limits

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ef08e09-1098-35cc-e053-2a95a90a3e1d
Retrieved
2026-09-05
DailyMed Set ID
9ef08e09-1098-35cc-e053-2a95a90a3e1d
Renal-function method
Creatinine clearance in mL/min for ESRD restriction
Source date/version
Revision not captured; retrieval date is not the revision date.
Hash meaning
SHA-256 identifies this local summary, not original SPL XML or a label PDF.
Local summary SHA-256
1b6f6c062280a715268bd58ffc53a0d8f8b639846bfe799ee7ccfdc4e37e7f20
Official

NURTEC-ODT: selected primary-label renal guidance and limits

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Adult NURTEC ODT for its labeled migraine uses; an orally disintegrating tablet, not an intranasal CGRP product.

Renal method: CrCl, mL/min; ESRD avoidance below 15
Source date: Revision date not captured in selected review; retrieval date is not revision date.
Retrieved: 2026-11-07

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Before using this finding

CrCl <15: avoid; ESRD and dialysis not studied.

Dialysis evidence: No dialysis regimen established in selected content

Selected sections checked against the identified source; not a complete monograph or independent clinician approval.

Section 8.7

No renal adjustment is required in mild, moderate or severe impairment. ESRD and dialysis populations have not been studied; avoid use with CrCl <15 mL/min. Do not infer a post-dialysis supplemental dose from low dialyzability. Preserve indication-specific frequency limits and interaction restrictions.

RDM72-rimegepant-nurtec-odt-label-1 · Source locator: Section 8.7

Source-specific limits

Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ef08e09-1098-35cc-e053-2a95a90a3e1d
Retrieved
2026-11-07
Renal-function method
CrCl, mL/min; ESRD avoidance below 15
Source date/version
Revision date not captured in selected review; retrieval date is not revision date.
Hash meaning
Locally authored summary text; not original source HTML, XML or PDF bytes
Local summary SHA-256
3175502182c4b11867cdd4e151f3652a06215335de563825fd433f0f859819fb
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

NURTEC-ODT: selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / label mirror · Adult NURTEC ODT for its labeled migraine uses; an orally disintegrating tablet, not an intranasal CGRP product.

Renal method: CrCl, mL/min; ESRD avoidance below 15
Source date: Revision date not established in reviewed mirror passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Before using this finding

CrCl <15: avoid; ESRD and dialysis not studied.

Dialysis evidence: No dialysis regimen established in selected content

Selected sections checked against the identified source; not a complete monograph or independent clinician approval.

Section 8.7

The mirror reports no adjustment for mild/moderate/severe impairment, no ESRD/dialysis studies, and avoidance below CrCl 15. Absence of a routine adjustment must not hide the ESRD restriction.

RDM72-rimegepant-nurtec-odt-rx-1 · Source locator: Section 8.7

Source-specific limits

Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/nurtec-odt-drug/
Retrieved
2026-11-07
Renal-function method
CrCl, mL/min; ESRD avoidance below 15
Source date/version
Revision date not established in reviewed mirror passage.
Hash meaning
Locally authored summary text; not original source HTML, XML or PDF bytes
Local summary SHA-256
9ccdac45a24d413f22cfeeb2530a148d241a750ccd765e61bb5ccad5575baf0a

Provenance and preservation

Additional summaries stored on this page: 2 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ef08e09-1098-35cc-e053-2a95a90a3e1d
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
26f6f77a05dbe7ad33c1720a0cb0ab67b6e6de44cb097c4c2787f0f36b160b5a
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report
Top